DATHYRCA guidelines - Dahanca
DATHYRCA guidelines - Dahanca
DATHYRCA guidelines - Dahanca
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Guidelines - Thyreoideacancer – revideret oktober 2005<br />
104. Chen H, Udelsman R. Papillary thyroid carcinoma: justification for total thyroidectomy and management<br />
of lymph node metastases. Surg.Oncol.Clin.N.Am. 1998;7:645-63.<br />
105. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary<br />
thyroid carcinoma. J.Clin.Endocrinol.Metab 1990;71:414-24.<br />
106. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA et al. The results of various<br />
modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients.<br />
J.Clin.Endocrinol.Metab 1992;75:714-20.<br />
107. Mazzaferri EL, Jhiang SM. Differentiated thyroid cancer long-term impact of initial therapy.<br />
Trans.Am.Clin.Climatol.Assoc. 1994;106:151-68.<br />
108. Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB. Papillary and follicular<br />
thyroid cancer: impact of treatment in 1578 patients. Int.J.Radiat.Oncol.Biol.Phys. 1988;14:1063-75.<br />
109. Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P et al. Long-term results<br />
and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985;55:794-804.<br />
110. Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD et al. Radioactive<br />
iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma.<br />
J.Nucl.Med. 1996;37:598-605.<br />
111. Haggerty MF, Murphy TM. Metastatic anaplastic thyroid carcinoma to the right ventricle of the heart.<br />
AJR Am.J.Roentgenol. 1990;155:1136.<br />
112. Siddiqi A, Foley RR, Britton KE, Sibtain A, Plowman PN, Grossman AB et al. The role of 123Idiagnostic<br />
imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to<br />
131I-scanning: avoidance of negative therapeutic uptake due to stunning. Clin.Endocrinol.(Oxf)<br />
2001;55:515-21.<br />
113. Brierley J, Maxon HR. Thyroid Cancer. Boston: Kluwer Academic Publishers, 1998:285-317.<br />
114. Schlumberger M, Mancusi F, Baudin E, Pacini F. 131I therapy for elevated thyroglobulin levels. Thyroid<br />
1997;7:273-6.<br />
115. Goldman JM, Line BR, Aamodt RL, Robbins J. Influence of triiodothyronine withdrawal time on 131I<br />
uptake postthyroidectomy for thyroid cancer. J.Clin.Endocrinol.Metab 1980;50:734-9.<br />
116. Sundhedsstyrelsen. Bekendtgørelse om anvendelse af åbne radioaktive kilder på sygehuse, laboratorier<br />
mv. 23-10-2000.<br />
Ref Type: Statute<br />
117. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA et al. Serum thyroglobulin<br />
autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance<br />
in patients with differentiated thyroid carcinoma. J.Clin.Endocrinol.Metab 1998;83:1121-7.<br />
118. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C et al. Prediction of disease status by<br />
recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid<br />
carcinoma. J.Clin.Endocrinol.Metab 2001;86:5686-90.<br />
119. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and<br />
follicular thyroid cancer. J.Clin.Endocrinol.Metab 2001;86:1447-63.<br />
120. Baudin E, Do CC, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive predictive value<br />
56
Change language